Gemifloxacin

Standigm announces Younsung Choo as chief executive officer

Retrieved on: 
Wednesday, April 12, 2023
Drug discovery, Artificial intelligence, R, FDA, Drug development, Food, Gemifloxacin, Choo, Pharmaceutical industry

SEOUL, South Korea, April 12, 2023 /PRNewswire/ -- Standigm, a company using artificial intelligence (AI) technology for drug discovery and development, announced that Younsung Choo has been appointed Chief Executive Officer (CEO). As the new CEO of Standigm, Choo will focus primarily on company strategy, planning, R&D and business development. 

Key Points: 
  • SEOUL, South Korea, April 12, 2023 /PRNewswire/ -- Standigm , a company using artificial intelligence (AI) technology for drug discovery and development, announced that Younsung Choo has been appointed Chief Executive Officer (CEO).
  • As the new CEO of Standigm, Choo will focus primarily on company strategy, planning, R&D and business development.
  • Choo is no stranger to Standigm.
  • Some of his achievements include:
    "We are thrilled that Younsung Choo is our new CEO," said Carl Foster, chief business officer.

FDA updates warnings for fluoroquinolone antibiotics on risks of mental health and low blood sugar adverse reactions

Retrieved on: 
Tuesday, July 10, 2018
Fluoroquinolone antibiotics, Chemistry, RTT, Piperazines, Organic chemistry, Cyclopropanes, Otologicals, Quinolone antibiotic, Levofloxacin, Ofloxacin, Ciprofloxacin, Gemifloxacin

FDA-approved fluoroquinolones include levofloxacin (Levaquin), ciprofloxacin (Cipro), ciprofloxacin extended-release tablets, moxifloxacin (Avelox), ofloxacin, gemifloxacin (Factive) and delafloxacin (Baxdela).

Key Points: 
  • FDA-approved fluoroquinolones include levofloxacin (Levaquin), ciprofloxacin (Cipro), ciprofloxacin extended-release tablets, moxifloxacin (Avelox), ofloxacin, gemifloxacin (Factive) and delafloxacin (Baxdela).
  • The safety labeling changes the FDA is requiring today were based on a comprehensive review of the FDA's adverse event reports and case reports published in medical literature.
  • Across the fluoroquinolone antibiotic class, a range of mental health side effects are already described in the Warnings and Precautionssection of the drug labeling, but differed by individual drug.
  • Today, the FDA also published a drug safety communication about safety information regarding hypoglycemic coma and mental health side effects with fluoroquinolones.